The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.
 
Nadia Hindi
Honoraria - PharmaMar
Research Funding - Adaptimmune (Inst); Amgen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daychii (Inst); Deciphera (Inst); Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Evan Rosenbaum
No Relationships to Disclose
 
Emily Jonczak
No Relationships to Disclose
 
Rainer Hamacher
Speakers' Bureau - Lilly
Research Funding - Deutsche Forschungsgemeinschaft
Travel, Accommodations, Expenses - Lilly; Novartis; PharmaMar
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Lilly; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sanofi
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Lilly; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Anthony Skryd
No Relationships to Disclose
 
Elizabeth Connolly
Travel, Accommodations, Expenses - cerner
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Antonio Gutierrez
No Relationships to Disclose
 
Carolina Bogefors
No Relationships to Disclose
 
Hans Gelderblom
Research Funding - Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
 
Kjetil Boye
No Relationships to Disclose
 
Clemence Henon
No Relationships to Disclose
 
Javier Martinez-Trufero
Consulting or Advisory Role - Eisai; PharmaMar; Sanofi
Research Funding - Blueprint Medicines (Inst); Lilly (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Amgen; Merck; PharmaMar; PharmaMar
 
Jose A. Lopez-Martin
No Relationships to Disclose
 
Andrés Redondo
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche
Research Funding - Eisai (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar
 
Claudia Valverde
No Relationships to Disclose
 
Bruno Vincenzi
No Relationships to Disclose
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - AbMaxBio; Adcendo; Agios; Ayala Pharmaceuticals; Blueprint Medicines; C4 Therapeutics; Daiichi Sankyo; Deciphera; EMD Serono; Kowa Pharmaceutical; Lilly; Mundipharma; NanoCarrier; Servier
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Javier Martin Broto
Honoraria - Bayer; Eisai; Lilly; PharmaMar
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar